Variable |  | HEMO (n = 23) | Placebo (n = 21) | p Value |
---|---|---|---|---|
Age (yr) |  | 52.65 ± 6.14 | 54.19 ± 5.99 | 0.53‡ |
Male/Female N (%) | Â | 9(39.1)/14(60.9) | 10(47.6)/11(52.4) | 0.57** |
Duration of diabetes (yr) |  | 6.26 ± 3.1 | 6.76 ± 4.47 | 0.66‡ |
Hypolipidemic agents N (%) | Metformin | 6 (26.1) | 10 (47.6) | 0.37** |
 | Metformin + Glibenclamide | 14 (60.9) | 10 (47.6) | |
 | Metformin + Repaglinide | 2 (8.7) | 0 (00) | |
 | Metformin + Glibenclamide + Repaglinide | 1 (4.3) | 1 (4.8) | |
Hypolipidemic agents N (%) | Atorvastatin | 17 (73.9) | 15 (71.4) | 0.85** |
Hypotensive agents N (%) | Losartan | 10 (43.5) | 10 (47.6) | 0.78** |